1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,490 | 0,530 | 16:21 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.01. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 24.12.24 | PTIX-Aktie erreicht 52-Wochen-Tief bei 0,45 US-Dollar | 1 | Investing.com Deutsch | ||
| 24.12.24 | PTIX stock touches 52-week low at $0.45 amid market challenges | 1 | Investing.com | ||
| 20.12.24 | Protagenic Therapeutics files to sell 5.84M shares | 5 | Seeking Alpha | ||
| 20.12.24 | Protagenic Therapeutics, Inc.\new - S-1, General form for registration of securities | - | SEC Filings | ||
| 03.12.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 02.12.24 | PTIX-Aktie fällt auf 52-Wochen-Tief von 0,48 US-Dollar | 4 | Investing.com Deutsch | ||
| 02.12.24 | PTIX stock touches 52-week low at $0.48 amid market challenges | 5 | Investing.com | ||
| 22.11.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 05.11.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million | 329 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that... ► Artikel lesen | |
| 05.11.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
| 29.10.24 | Protagenic Therapeutics announces $1.275 million stock sale | 3 | Investing.com | ||
| 29.10.24 | Protagonist Therapeutics: Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million | 284 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it... ► Artikel lesen | |
| 18.09.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 14.08.24 | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.08.24 | PTIX stock touches 52-week low at $0.6 amid market challenges | 1 | Investing.com | ||
| 22.05.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychi | 299 | ACCESS Newswire | No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to CommenceInvestor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact... ► Artikel lesen | |
| 01.05.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial | 598 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion... ► Artikel lesen | |
| 17.04.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit | 560 | ACCESS Newswire | Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical... ► Artikel lesen | |
| 01.04.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results | 334 | ACCESS Newswire | Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,702 | -3,49 % | CureVac Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| VALNEVA | 2,282 | +4,20 % | Valneva: Hohe Immunantwort durch Chikungunya-Impfstoff | Valneva hat neue Phase-3-Daten für den Chikungunya-Impfstoff IXCHIQ veröffentlicht, die eine anhaltend hohe Immunantwort bei Jugendlichen bestätigen. Ein Jahr nach der einmaligen Impfung zeigten Studienteilnehmer... ► Artikel lesen | |
| BIOFRONTERA | 2,505 | 0,00 % | Biofrontera files to sell 5.72M shares of common stock by selling shareholders | ||
| PALATIN TECHNOLOGIES | 0,905 | -0,88 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,200 | +0,92 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 1,120 | +0,96 % | Sangamo To Regain Rights To Hemophilia Therapy After Pfizer's Decides To Terminate Collaboration | NEW YORK CITY (dpa-AFX) - Genomic medicine company Sangamo Therapeutics, Inc. (SGMO) Monday announced that it will regain development and commercialization rights to giroctocogene fitelparvovec... ► Artikel lesen | |
| INFLARX | 2,366 | -1,91 % | InflaRx: Zulassung! | Die deutsche Biotech-Gesellschaft InflaRx kann einen wichtigen Meilenstein verbuchen. Denn die Europäische Kommission hat die Zulassung für Gohibic (Vilobelimab) zur Behandlung des SARS-CoV-2-induzierten... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,041 | -2,41 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -2,55 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,260 | -4,49 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| EDITAS MEDICINE | 1,321 | +2,25 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 112,15 | +0,63 % | Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory | ||
| BLUEBIRD BIO | 7,300 | -3,18 % | bluebird bio Announces 1-for-20 Reverse Stock Split | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock... ► Artikel lesen | |
| GERON | 2,819 | -2,02 % | Geron Gets Positive CHMP Opinion For RYTELO In Transfusion-Dependent Anemia Due To Lower-Risk MDS | WASHINGTON (dpa-AFX) - Geron Corporation (GERN), a commercial-stage biopharmaceutical company, Friday said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,979 | +3,78 % | Microbot Medical Inc.: Microbot Medical Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY |
Das Unternehmen PROTAGENIC THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -100,00 % bei einem Aktienkurs von 0,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROTAGENIC THERAPEUTICS INC finden Sie auf Wallstreet Online.
